Fig. 2
From: Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors
PTEN mutations sensitize endometrial cancer cells to PARP inhibitors. In a clonogenic assay at day 5 (D5), the sensitivity to olaparib is higher for the PTEN mutated cell lines, Ishikawa and AN3CA compared to the PTEN wild-type cell lines, HEC-50 and HEC-B1 (a). BMN-673 shows a higher efficiency of inhibitory activity than olaparib in all cell lines (b). The transfected shPTEN cell lines were more sensitive to both olaparib and BMN-637 compared to their wild type PTEN counterparts c and d which confirms the higher sensitivity to PARP-inhibitors when PTEN is mutated